Literature DB >> 3732387

Molecular distinction between calf heart and brain muscarine receptors: different N-ethylmaleimide modulation of agonist binding.

P Vanderheyden, L Kanarek, G Vauquelin.   

Abstract

Muscarinic acetylcholine receptors in calf heart and forebrain membranes were identified by binding of 1-[benzilic-4,4'-3H]quinuclidinyl benzilate ([3H]QNB). We were able to solubilise these receptors with a yield of 50% of the proteins by treatment of the membranes with digitonin. The existence of two or more receptor subclasses with different agonist affinity in the heart membranes was evidenced by the shallow carbachol/[3H]QNB competition binding curves. The receptors displayed only low agonist affinity, in the presence of GTP as well as after solubilisation. The alkylating reagent N-ethylmaleimide (NEM) caused a 70-fold increase in agonist affinity for the solubilised receptors whereas GTP was ineffective. A similar difference in affinity was observed for the membranes when agonist competition curves in the presence of NEM were compared to those in the presence of GTP. NEM caused only a 2- to 3-fold increase of the agonist affinity for solubilised brain cortex membranes. These data suggest that heart and brain muscarine receptors are structurally different.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732387     DOI: 10.1016/0014-2999(86)90091-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study.

Authors:  Carlos Casasnovas; Montserrat Ruiz; Aurora Pujol; Agatha Schlüter; Alba Naudí; Stéphane Fourcade; Misericordia Veciana; Sara Castañer; Antonia Albertí; Nuria Bargalló; Maria Johnson; Gerald V Raymond; Ali Fatemi; Ann B Moser; Francesc Villarroya; Manuel Portero-Otín; Rafael Artuch; Reinald Pamplona
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.